Search Results - "COHEN, J. A"

Refine Results
  1. 1

    Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy by Francis, G, Kappos, L, O’Connor, P, Collins, W, Tang, D, Mercier, F, Cohen, JA

    Published in Multiple sclerosis (01-04-2014)
    “…Background: Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. Objective: The objective of this article is…”
    Get full text
    Journal Article
  2. 2

    Differential diagnosis of suspected multiple sclerosis: a consensus approach by Miller, DH, Weinshenker, BG, Filippi, M, Banwell, BL, Cohen, JA, Freedman, MS, Galetta, SL, Hutchinson, M, Johnson, RT, Kappos, L, Kira, J, Lublin, FD, McFarland, HF, Montalban, X, Panitch, H, Richert, JR, Reingold, SC, Polman, CH

    Published in Multiple sclerosis (01-11-2008)
    “…Background and objectives Diagnosis of multiple sclerosis (MS) requires exclusion of diseases that could better explain the clinical and paraclinical findings…”
    Get full text
    Journal Article Conference Proceeding
  3. 3

    A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals by Leslie, Michael A, Cohen, Daniel J A, Liddle, Danyelle M, Robinson, Lindsay E, Ma, David W L

    Published in Lipids in health and disease (06-06-2015)
    “…Circulating levels of triacylglycerol (TG) is a recognized risk factor for developing cardiovascular disease, a leading cause of death worldwide. The Institute…”
    Get full text
    Journal Article
  4. 4

    Dose comparison trial of sustained-release fampridine in multiple sclerosis by GOODMAN, A. D, BROWN, T. R, COHEN, J. A, KRUPP, L. B, SCHAPIRO, R, SCHWID, S. R, COHEN, R, MARINUCCI, L. N, BLIGHT, A. R

    Published in Neurology (07-10-2008)
    “…To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS). This multicenter,…”
    Get full text
    Journal Article
  5. 5
  6. 6

    A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis by Vollmer, T. L., Sorensen, P. S., Selmaj, K., Zipp, F., Havrdova, E., Cohen, J. A., Sasson, N., Gilgun-Sherki, Y., Arnold, D. L.

    Published in Journal of neurology (01-04-2014)
    “…The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and descriptively compared laquinimod…”
    Get full text
    Journal Article
  7. 7

    Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis by CREE, B. A. C, KHAN, O, HAINES, J. L, PERICAK-VANCE, M, DELOA, C, OKSENBERG, J. R, HAUSER, S. L, BOURDETTE, D, GOODIN, D. S, COHEN, J. A, MARRIE, R. A, GLIDDEN, D, WEINSTOCK-GUTTMAN, B, REICH, D, PATTERSON, N

    Published in Neurology (14-12-2004)
    “…African American (AA) individuals are thought to develop multiple sclerosis (MS) less frequently than Caucasian American (CA) individuals. To compare the…”
    Get full text
    Journal Article
  8. 8
  9. 9

    Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis by BAIER, M. L, CUTTER, G. R, RUDICK, R. A, MILLER, D, COHEN, J. A, WEINSTOCK-GUTTMAN, B, MASS, M, BALCER, L. J

    Published in Neurology (22-03-2005)
    “…To evaluate concurrent and predictive validity for low-contrast letter acuity (L-CLA) testing as a candidate visual component for the Multiple Sclerosis…”
    Get full text
    Journal Article
  10. 10

    A Phenomenological One-Parameter Equation of State for Osmotic Pressures of PEG and Other Neutral Flexible Polymers in Good Solvents by Cohen, J. A, Podgornik, R, Hansen, P. L, Parsegian, V. A

    Published in The journal of physical chemistry. B (26-03-2009)
    “…We present a phenomenological one-parameter scaling equation of state that accurately represents osmotic pressures of neutral flexible polymers in good…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study by Goodman, A.D., Cohen, J.A., Cross, A., Vollmer, T., Rizzo, M., Cohen, R., Marinucci, L., Blight, A.R.

    Published in Multiple sclerosis (01-04-2007)
    “…Objective To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg…”
    Get full text
    Journal Article
  13. 13

    Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS by COHEN, J. A, IMREY, P. B, HUTTON, G. J, MANDELL, B. F, SCOTT, T. F, ZHANG, H, APPERSON-HANSEN, C, BECK, G. J, HOUGHTALING, P. L, KARAFA, M. T, STADTLER, M, CALABRESI, P. A, EDWARDS, K. R, EICKENHORST, T, FELTON, W. L, FISHER, E, FOX, R. J, GOODMAN, A. D, HARA-CLEAVER, C

    Published in Neurology (10-02-2009)
    “…To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNbeta-1a) combined with methotrexate (MTX), i.v. methylprednisolone (IVMP), or both…”
    Get full text
    Journal Article
  14. 14

    Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite by BALCER, L. J, BAIER, M. L, HEIDENREICH, F. R, JACOBS, D. A, MARKOWITZ, C. E, STUART, W. H, YING, G.-S, GALETTA, S. L, MAGUIRE, M. G, CUTTER, G. R, COHEN, J. A, KOOIJMANS, M. F, SANDROCK, A. W, NANO-SCHIAVI, M. L, PFOHL, D. C, MILLS, M, BOWEN, J, FORD, C

    Published in Neurology (25-11-2003)
    “…Visual dysfunction is one of the most common causes of disability in multiple sclerosis (MS). The Multiple Sclerosis Functional Composite (MSFC), a new…”
    Get full text
    Journal Article
  15. 15

    Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects by Weiner, H L, Cohen, J A

    Published in Multiple sclerosis (01-04-2002)
    “…Cyclophosphamide is an alkylating agent used to treat malignancies and immune-mediated inflammatory non-malignant processes such as lupus nephritis and…”
    Get full text
    Journal Article
  16. 16

    Randomized controlled trial of atorvastatin in clinically isolated syndrome: The STAyCIS study by WAUBANT, E, PELLETIER, D, SCHWID, S, GOODMAN, A, KACHUCK, N, PREININGEROVA, J, WEINSTOCK-GUTTMAN, B, CALABRESI, P. A, MILLER, A, MOKHTARANI, M, IKLE, D, MURPHY, S, MASS, M, KOPETSKIE, H, DING, L, ROSENBERG, E, SPENCER, C, ZAMVIL, S. S, COHEN, J. A, KITA, M, CROSS, A, BAR, A, VOLLMER, T, RACKE, M, STIIVE, O

    Published in Neurology (10-04-2012)
    “…To test efficacy and safety of atorvastatin in subjects with clinically isolated syndrome (CIS). Subjects with CIS were enrolled in a phase II, double-blind,…”
    Get full text
    Journal Article
  17. 17

    Assessing disability progression with the Multiple Sclerosis Functional Composite by Rudick, RA, Polman, CH, Cohen, JA, Walton, MK, Miller, AE, Confavreux, C, Lublin, FD, Hutchinson, M, O’Connor, PW, Schwid, SR, Balcer, LJ, Lynn, F, Panzara, MA, Sandrock, AW

    Published in Multiple sclerosis (01-08-2009)
    “…Background The initial Multiple Sclerosis Functional Composite (MSFC) proposal was a three-part composite of quantitative measures of ambulation, upper…”
    Get full text
    Journal Article
  18. 18
  19. 19
  20. 20

    THE FACE, BEAUTY, AND SYMMETRY: PERCEIVING ASYMMETRY IN BEAUTIFUL FACES by ZAIDEL, D. W., COHEN, J. A.

    Published in International journal of neuroscience (01-08-2005)
    “…The relationship between bilateral facial symmetry and beauty remains to be clarified. Here, straight head-on photographs of "beautiful" faces from the…”
    Get full text
    Journal Article